Search results for "Cell-mediated cytotoxicity"

showing 10 items of 26 documents

Immuntherapie des Kolorektalkarzinoms - aktueller Stand und Perspektiven

2006

The specific immunotherapy of colorectal cancer initially revealed promising results. However, a significant clinical benefit for patients has still to be proven in phase III trails. In order to compare the different clinical approaches and early phase I - II studies, there is an urgent need for the establishment and acceptance of new standardized diagnostic tools for detecting and quantifying induced and clinical relevant immune responses in patients. Whether or not subgroups with a certain genetic background, such as specific HLA alleles, reveal a better benefit from tumour vaccinations needs to be further analysed. Currently, only two specific antibodies, targeting membraneous receptors …

Antibody-dependent cell-mediated cytotoxicitybiologyColorectal cancerbusiness.industrymedicine.medical_treatmentGastroenterologyHuman leukocyte antigenImmunotherapymedicine.diseaseClinical trialVaccinationImmune systemImmunologymedicinebiology.proteinAntibodybusinessZeitschrift für Gastroenterologie
researchProduct

Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy

2010

Monoclonal antibodies (mAbs) constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The treatment of B-cell malignancies and HER2/Neu+ breast cancer has benefited considerably from the use of therapeutic mAbs, either alone or in combination with standard chemotherapy. Frequent relapses, however, demonstrate that the bioactivity of these mAbs is still suboptimal. The concept of improving the anti-tumor activity of mAbs is well established and potentiating the cytotoxicity induced by anticancer mAbs can be achieved by strategies that target the downstream cytolytic effector cells. The recruitment of Fcγ receptor-dependent function…

Antibody-dependent cell-mediated cytotoxicitybiologybusiness.industrymedicine.drug_classmedicine.medical_treatmentT cellGeneral MedicineImmunotherapyMonoclonal antibodyBiochemistrymedicine.anatomical_structureAntigenCancer immunotherapyImmunologybiology.proteinMolecular MedicineMedicineAntibodybusinessCytotoxicityMolecular BiologyCurrent Molecular Medicine
researchProduct

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymp…

2018

Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 20% of pediatric and adult ALL cases. Despite the use of intensive chemotherapy protocols, 25% of children and 50% of adult patients fail to respond or relapse. The 3-years prognosis for these patients is poor and novel treatment options are needed. The targeting of tumor-associated antigens by monoclonal antibodies (mAb) is among the most investigated immune-therapeutic strategies. Accordingly, we developed a new humanized mAb (hUMG1), directed against a heavy glycosylated epitope of CD43 which presents a high reactivity against T-ALL cells. Here we investigated the pre-clinical therapeutic activity and t…

Antibody-dependent cell-mediated cytotoxicitybiologymedicine.diagnostic_testmedicine.drug_classbusiness.industryImmunologyCell BiologyHematologyMonoclonal antibodymedicine.diseaseBiochemistryEpitopeFlow cytometryLeukemiaAntigenCancer researchmedicinebiology.proteinImmunohistochemistryAntibodybusinessBlood
researchProduct

K Cell Activity of Normal and Chronic Lymphocytic Leukaemia Lymphocytes: Association with Lymphocytes bearing Receptors for Human C3b

1977

Surface properties of effector cells in antibody-dependent cell mediated cytotoxicity (ADCC) are at present under intensive investigation. Among these cells a lymphocyte population (K cells) has been described with receptors for the Fc portion of IgG (4), receptors for complement (11) and lacking receptors for sheep red blood cells (SRBC) and surface immunoglobulin (13). The purpose of the present study was to investigate more thoroughly the relationship between K cell activity in ADCC and cells bearing receptors for C3b and C3d.

Antibody-dependent cell-mediated cytotoxicityeducation.field_of_studyLymphocytic leukaemiaSurface ImmunoglobulinEffectorChemistryLymphocytePopulationchemical and pharmacologic phenomenak-cellMolecular biologymedicine.anatomical_structuremedicineReceptoreducation
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct

γδ T cells as a potential tool in colon cancer immunotherapy

2014

γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, the combined upregulation of T-cell receptorand NKG2D ligands on tumor cells and induction of NKG2D expression on γδ T cells may greatly enhance tumor killing and unlock the functions of γδ T cells. Here, we briefly review current data on the mechanisms of γδ T-cell recognition and killing of colon cancer cells and propose that γδ T cells may represent a promising target for the…

Cytotoxicity ImmunologicColorectal cancermedicine.medical_treatmentImmunologyNkg2d ligandsLarge rangeLigandsDownregulation and upregulationT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyIn patientCell-mediated cytotoxicitybusiness.industryReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.diseaseNKG2Dgamma delta cellcolon cancerOncologyColonic NeoplasmsImmunologyNeoplastic Stem CellsImmunotherapybusinessImmunotherapy
researchProduct

Cellular cytotoxicity against the human hepatoma cell line PLC/PRF/5 in patients with hepatitis B virus-induced chronic active hepatitis (CAH) and no…

2008

Hepatitis B virusHepatitisHepatologybusiness.industryChronic Activemedicine.disease_causemedicine.diseaseVirologyPlc prf 5Hepatoma cell linemedicineIn patientCell-mediated cytotoxicitybusinessLiver
researchProduct

Effects of nordihydroguaiaretic acid on murine antibody-dependent cellular cytotoxicity.

1996

The purpose of this study was to analyze the effects of nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway of arachidonic acid, on antibody-dependent cellular cytotoxicity. Antibody-dependent cellular cytotoxicity mediated by murine spleen cells was significantly inhibited by concentrations of nordihydroguaiaretic acid from 10(-5) to 10(-4) M (1C50 = 2 x 10(-5) M). The inhibitory effect of nordihydroguaiaretic acid was also observed on antibody-dependent cellular cytotoxicity mediated by macrophage-depleted spleen cells as well as isolated macrophages. Nordihydroguaiaretic acid was highly effective when added at the beginning of the assay and was always present throughout t…

Leukotriene B4Clinical BiochemistrySpleenIn Vitro TechniquesLeukotriene B4chemistry.chemical_compoundLipoxygenaseMicemedicineAnimalsMasoprocolLipoxygenase InhibitorsCytotoxicityAntibody-dependent cell-mediated cytotoxicityMice Inbred BALB CbiologyMacrophagesAntibody-Dependent Cell CytotoxicityNordihydroguaiaretic acidKineticsmedicine.anatomical_structurechemistryBiochemistryEnzyme inhibitorbiology.proteinArachidonic acidSpleenInternational journal of clinicallaboratory research
researchProduct

Selective Inhibition of Human Natural Killing and Antibody-Dependent Cellular Cytotoxicity by a Polyanion

1987

A high molecular polyanion, Liquoid, was found to inhibit at nontoxic concentrations (12-50 micrograms/ml) the natural killing (NK) and the antibody-dependent cellular cytotoxic (ADCC) activity of human peripheral blood mononuclear cells selectively. Whereas NK of the K 562 target cell was slightly or not at all affected, the spontaneous lysis of PDe-B-1, an EBV-transformed B-cell line, was strongly inhibited or even completely abolished. ADCC activity could only be inhibited by Liquoid if the target cells were mycoplasma-free, while the polyanion had no effect when mycoplasma-contaminated target cells were used. Liquoid did not alter the target binding capacity of the NK effector cells and…

MaleCellular immunityPolymersImmunologyAlpha interferonIn Vitro TechniquesBiologyT-Lymphocytes RegulatoryPeripheral blood mononuclear cellNatural killer cellImmune systemmedicineHumansCytotoxic T cellAntibody-dependent cell-mediated cytotoxicityImmunity CellularBenzenesulfonatesAntibody-Dependent Cell CytotoxicityGeneral MedicinePolyanetholesulfonatePolyelectrolytesVirologyMolecular biologyImmunity InnateCytolysismedicine.anatomical_structureFemaleInterferonsScandinavian Journal of Immunology
researchProduct

A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma

2005

WX-G250 is a chimeric monoclonal antibody that binds to carbonic anhydrase IX(G250/MN), which is present on greater than 95% of RCCs of the clear cell subtype. The suggested working mechanism of WX-G250 is by ADCC. Because the number of activated ADCC effector cells can be increased by a low dose interleukin-2 pulsing schedule, a multicenter study was initiated to investigate whether WX-G250 combined with LD-IL-2 could lead to an improved clinical outcome in patients with progressive RCC.A total of 35 patients with progressive clear cell RCC received weekly infusions of WX-G250 for 11 weeks combined with a daily LD-IL-2 regimen. Patients were monitored longitudinally for ADCC capacity. Radi…

OncologyAdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyMonoclonal antibodyTranslational research [ONCOL 3]Renal cell carcinomaInternal medicineCarcinomaMedicineHumansProspective StudiesCarcinoma Renal CellAgedAntibody-dependent cell-mediated cytotoxicitybiologybusiness.industryAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]ImmunotherapyMiddle Agedmedicine.diseaseKidney NeoplasmsImmunologybiology.proteinDisease ProgressionInterleukin-2Drug Therapy CombinationFemaleAntibodybusinessKidney cancerProgressive diseaseThe Journal of Urology
researchProduct